{
    "nct_id": "NCT02917083",
    "official_title": "Phase I Study of Relapsed CD30 Expressing Lymphoma Treated with CD30 CAR T Cells (RELY-30)",
    "inclusion_criteria": "1. Diagnosis of relapsed/refractory HL or NHL.\n2. CD30 positive tumor as assayed in a CLIA certified pathology laboratory (result can be pending at this time)\n3. Hgb â‰¥ 7.0 (may be a transfused value)\n4. Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent.\n5. Karnofsky or Lansky score of > 60%\n\nTREATMENT Inclusion Criteria:\n\n1. Diagnosis of relapsed/refractory HL or NHL.\n2. CD30-positive tumor as assayed in a CLIA certified pathology laboratory.\n3. Age 16 to 75 for the first three patients on a dose level; thereafter, if no DLT, patients aged 12 to 75 can be treated on that dose level.\n4. Bilirubin 1.5 times or less than the upper limit of normal.\n5. AST 3 times or less than the upper limit of normal.\n6. Estimated GFR > 70 mL/min.\n7. Pulse oximetry of > 90% on room air\n8. EKG shows no significant arrhythmias\n9. Karnofsky or Lansky score of > 60%.\n10. Available autologous T cells with greater than or equal to 15% expression of CD30CAR determined by flow-cytometry.\n11. Recovered from all acute non-hematologic toxic effects of all prior chemotherapy.\n12. Adequate pulmonary function with FEV1, FVC and DLCO (or DLCO/VA, as clinically appropriate) greater than or equal to 50% of expected corrected for hemoglobin.\n13. Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. The male partner should use a condom.\n14. Informed consent explained to, understood by and signed by patient or guardian.\n\nPROCUREMENT\nHealthy volunteers allowed\nMust have minimum age of 12 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "1. Active infection with HIV or HTLV (can be pending at this time).\n2. Active bacterial, fungal or viral infection.\n\nTREATMENT Exclusion Criteria:\n\n1. Currently receiving any investigational agents or received any tumor vaccines within the previous six weeks.\n2. Received anti-CD30 antibody-based therapy within the previous 4 weeks.\n3. Subjects with rapidly progressive disease, defined as kinetic failure to previous chemotherapy.\n4. Bulky disease (defined as a 10 cm mass or mediastinal disease with a transverse diameter exceeding 33% of the transthoracic diameter).\n5. History of hypersensitivity reactions to murine protein-containing products.\n6. Pregnant or lactating.\n7. Tumor in a location where enlargement could cause airway obstruction.\n8. Current use of systemic corticosteroids at a dose equivalent to 0.5 mg/kg/day of prednisone or higher.\n9. Active hemorrhagic cystitis.\n10. Active bacterial, viral or fungal infection.\n11. Symptomatic cardiac disease (NYHA Class III or IV disease).",
    "miscellaneous_criteria": "PROCUREMENT"
}